Universität Bonn has divulged P2X purinoceptor 4 (P2RX4; P2X4) antagonists reported to be useful as diagnostics and for the treatment of pain, inflammation, cancer, stroke, multiple sclerosis, atherosclerosis and obesity.
Hangzhou Zhongmei Huadong Pharmaceutical Co. Ltd. has synthesized proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety covalently bonded to a GTPase KRAS (G12D mutant) targeting moiety through a linker reported to be useful for the treatment of cancer.
University of Copenhagen has described cyclic peptides acting as postsynaptic density-95 (PSD-95) protein inhibitors reported to be useful for the treatment of neuropathic pain.
Scinnohub Pharmaceutical Co. Ltd. has divulged cyclin-dependent kinase (CDK) inhibitors, particularly CDK9 inhibitors, reported to be useful for the treatment of cancer.
Scientists at Helmholtz Zentrum fur Infektionsforschung GmbH and Lead Discovery Center GmbH have identified α-hemolysin (Staphylococcus aureus) inhibitors reported to be useful for the treatment of staphylococcal pneumonia.
Scientists at Shanghai Aryl Pharmtech Co. Ltd. and Zhejiang Hisun Pharmaceutical Co. Ltd. have synthesized kinesin-like protein KIF18A inhibitors reported to be useful for the treatment of cancer.
Haisco Pharmaceutical Group Co. Ltd. has disclosed integrin αvβ1 and/or integrin αvβ6 antagonists reported to be useful for the treatment of idiopathic pulmonary fibrosis (IPF).
Korea Institute of Science and Technology has described diosgenin derivatives reported to be useful for the treatment of depression, multiple sclerosis, ischemic stroke, schizophrenia, amyotrophic lateral sclerosis, neuroblastoma, Alzheimer’s disease and post-traumatic stress disorders.
RSS